Navigation Links
Rebiotix and McMaster Children's Hospital Announce First Patient treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis
Date:12/14/2015

ROSEVILLE, Minn. and HAMILTON, Ontario, Dec. 14, 2015 /PRNewswire/ -- Rebiotix Inc. and McMaster Children's Hospital announced the first patient treated in the PediFETCh (Pediatric FEcal microbial Transplant for ulcerative Colitis) trial. This is the largest randomized, placebo-controlled clinical trial to date evaluating fecal microbial transplant (FMT) in children with ulcerative colitis (UC). 

UC is an often debilitating gastroenterological condition that affects approximately 500,000 people in North America.1  Ulcerative colitis is characterized by chronic inflammation in the large intestine. In children, this condition can have profound effects on growth and development, and quality of life is affected by flares of abdominal pain, bloody diarrhea and treatments that may cause significant toxicity, lymphoma and serious infections.2 

The PediFETCh trial is being conducted through McMaster Children's Hospital's Division of Pediatric Gastroenterology and Nutrition, in collaboration with Rebiotix Inc., a clinical stage biotechnology company. RBX2660 is the company's lead drug platform for microbial restoration therapy, containing live microbes collected from screened human donors.

"We are excited to launch this study using RBX2660, to help understand the role of intestinal bacteria in the treatment of pediatric ulcerative colitis," said Nikhil Pai, MD FAAP FRCPC, the study's principal investigator who is a Pediatric Gastroenterologist at McMaster Children's Hospital and Assistant Professor of Pediatrics at McMaster University's Michael G. DeGroote School of Medicine. "By delivering a series of enemas containing live human bacteria into the intestines of children with UC, we may be able to alter the immune disruption that characterizes a disease that can be debilitating for children and their families."  

"Our collaboration with McMaster Children's Hospital exemplifies the passion and commitment of Rebiotix to apply our microbial restoration therapy platform to a range of challenging diseases such as ulcerative colitis," said Rebiotix CEO Lee Jones, "We remain focused on realizing the potential of the human microbiome to treat challenging gastrointestinal diseases."

The results of this pilot trial will help inform the design of a future, multicenter pediatric study that will evaluate fecal microbial transplant as a potential treatment option for inflammatory bowel disease.

Dr. Robert Issenman, (Division Chief of Pediatric Gastroenterology, McMaster Children's Hospital and Professor of Pediatrics at the Michael G. DeGroote School of Medicine at McMaster) has generously provided support and mentorship for the PediFETCh Trial. The study involves the expertise of co-investigators Dr. Christine Lee (Medical Director, Infection Prevention and Control, St. Joseph's Healthcare Hamilton and Professor of Pathology and Molecular Medicine at the Michael G. DeGroote School of Medicine at McMaster), Dr. Paul Moayyedi (Chair of Gastroenterology, Hamilton Health Sciences and Professor of Medicine at the Michael G. DeGroote School of Medicine at McMaster) and study coordinator, Ms. Jelena Popov, BSc (McMaster University).3

About Rebiotix Inc.

Rebiotix Inc. is a results-oriented biotechnology company focused on the treatment of challenging diseases by harnessing the power of the human microbiome. The Roseville, Minn. based company is pioneering Microbiota Restoration Therapy (MRT) for delivering live microbes into a sick patient's intestinal tract to treat disease. Rebiotix's lead candidate RBX2660 was granted Orphan Drug status, Fast Track status and Breakthrough Therapy Designation from the FDA for its potential that it may treat recurrent C diff infection. For more information, visit www.rebiotix.com.

About McMaster Children's Hospital

McMaster Children's Hospital is a dedicated pediatric academic health sciences center, providing care to 2.3 million children across South Central Ontario and beyond. It is the regional centre for children and teens requiring emergency care, inpatient and outpatient subspecialty services, and is home to the largest neonatal intensive care unit in Ontario. McMaster Children's Hospital is closely affiliated with the Farncombe Family Digestive Health Research Institute of McMaster University, a world-renowned multidisciplinary intestinal disease research facility, focused on the role of the gut microbiome in chronical intestinal disease. The Hospital's Division of Pediatric Gastroenterology maintains strong clinical and basic science collaborations with the Farncombe Institute, exploring the frontiers of inflammatory, functional, and diet-induced pediatric gastrointestinal disorders. For more information, visit www.mcmasterchildrenshospital.ca.

1 Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease; findings from two nationally representative Canadian surveys.  Inflamm Bowel Dis.  2006; 12:697-707

2 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies in inflammatory bowel disease. Am J Gastroenterol 2011: 106 supp 1: S2-S25.

3 Moayyedi P, Surette MG, Kim PT, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015;149(1):102-109.e6.

Rebiotix Media Contact:
Christy Maginn
646-280-5210
rebiotixmediainquiries@yr.com

Hamilton Health Sciences Media Contact:
Vel Snoukphonh
905-870-0111
snoukphv@hhsc.ca


'/>"/>
SOURCE Rebiotix Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Rebiotix Named 2015 Tekne Award Winner
2. Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
3. Rebiotix Receives Breakthrough Therapy Designation for RBX2660 -- A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
4. Rebiotix Inc. Receives $25M for Series B Funding
5. PTC Therapeutics and Massachusetts General Hospital Collaborate on Rare Disease Research
6. MiMedx Updates The Status Of Its More Than 5,400 U.S. Hospitals Under Contract
7. uBiome and CDC Partner to Study Hospital Acquired Infections
8. Stuart H. Orkin, MD, honored with Lifetime Impact Award at Boston Childrens Hospital Innovation Summit
9. Boston Childrens Hospital presents Vijay G. Sankaran, MD, PhD, with Rising Star Award at Global Pediatric Innovation Summit
10. Parker Road Veterinary Hospital is Now Offering Stem Cell Therapy for Dogs and Cats
11. 2016 Emerging Strategies for the German Hospital Hematology and Flow Cytometry Markets - Product Development Opportunities for Instruments, Consumables, and Auxiliary Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant Incorporated Founder and ... technology at the IMCAS Innovation Shark Tank 2020 in Paris, France in January. ... and aesthetic science industries that promise to revolutionize medical practices in their fields. ...
(Date:2/21/2020)... TORONTO (PRWEB) , ... February ... ... demonstrates an exquisite capability to perform complex, efficient and elegant chemistry. Humans ... and algorithms to our own goals. , Through rapidly evolving technologies and ...
(Date:2/19/2020)... ... February 18, 2020 , ... Intech ... launch of a new and unified global brand identity, as it celebrates its ... engineering challenges, as well as an enthusiasm for designing and manufacturing state-of-the-art medical ...
(Date:2/10/2020)... ... February 10, 2020 , ... R3 Medical Training announced it is ... 2020 in Las Vegas. The course is hands on involving real patients and stem ... few years, the Comprehensive Stem Cell Training Course has received rave reviews from attendees, ...
Breaking Biology Technology:
(Date:3/20/2020)... AUSTIN, Texas and OKLAHOMA CITY (PRWEB) , ... March 20, 2020 ... ... toward the development of a vaccine for the COVID-19 virus. The scientific team is ... target and kill virus-infected cells. He will be working with Pure MHC, part of ...
(Date:3/19/2020)... ... March 17, 2020 , ... Shoreline ... down to the strain level, recently unveiled a convenient new solution for the ... the same innovative amplification capabilities as the Shoreline Complete kit. It is a ...
(Date:3/13/2020)... ... March 13, 2020 , ... Cryo-Cell International’s announcement ... blood performed by Dr. Hal Boxmeyer and colleagues, which determined sample viability of ... cells under proper conditions. Cryo-Cell International marks the first family cord blood bank ...
Breaking Biology News(10 mins):